IL6 and congenital rubella syndrome: Given the critical role of IL-6 and IL-1 in CRS, the corresponding IL-6R inhibitors (Tocilizumab) and IL-1R inhibitors (Anakinra) have been identified for their effectiveness in treatment (19, 108, 109).